ECSS
HAE icon

Eurizon Capital SGR SpA’s Haemonetics HAE Stock Holding History

Eurizon Capital SGR SpA’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$78.9K Hold
1,049
– – ﹤0.01% 953
2026
Q1 		$57.9K Hold
1,049
– – ﹤0.01% 998
2025
Q4 		$84.8K Buy
+1,049
New +$70.5K ﹤0.01% 825

Other funds holding HAE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Eurizon Capital SGR SpA's HAE Position: Q2 2026 in Review

Eurizon Capital SGR SpA held its Haemonetics (HAE) position steady in Q2 2026 at 1,049 shares worth $78.9K. The position accounts for ﹤0.01% of the portfolio, ranked #953.

Eurizon Capital SGR SpA first reported a position in HAE in Q4 2025 and has held it in 3 quarters since. The position peaked at $84.8K in Q4 2025. 329 funds tracked by Wall St. Rank hold HAE as of Q2 2026.

  • Eurizon Capital SGR SpA held 1,049 shares of Haemonetics worth $78.9K as of Q2 2026.
  • Eurizon Capital SGR SpA left its Haemonetics share count unchanged in Q2 2026.
  • Haemonetics made up ﹤0.01% of Eurizon Capital SGR SpA's portfolio in Q2 2026, its #953 holding.
  • Eurizon Capital SGR SpA first reported a position in Haemonetics in Q4 2025 and has held it in 3 quarters since.
  • Eurizon Capital SGR SpA's Haemonetics position peaked at $84.8K in Q4 2025.
  • 329 funds tracked by Wall St. Rank held Haemonetics as of Q2 2026.

Based on Eurizon Capital SGR SpA's 13F filing for Q2 2026, filed 29 Jul 2026.